Background and purpose: Pain is highly prevalent in Parkinson's disease (PD), impacting patients' ability, mood and quality of life. Detecting the presence of pain in its multiple modalities is necessary for adequate personalized management of PD. A 14-item, PD-specific, patient-based questionnaire (the King's Parkinson's Disease Pain Questionnaire, KPPQ) was designed corresponding to the rater-based KPP Scale (KPPS). The present multicentre study was aimed at testing the validity of this screening tool. Methods: First, a comparison between the KPPQ scores of patients and matched controls was performed. Next, convergent validity, reproducibility (test-retest) and diagnostic performance of the questionnaire were analysed. Results: Data from 300 patients and 150 controls are reported. PD patients declared significantly more pain symptoms than controls (3.96 AE 2.56 vs. 2.17 AE 1.39; P < 0.0001). The KPPQ convergent validity was high with KPPS total score (r S = 0.80) but weak or moderate with other pain assessments. Test-retest reliability was satisfactory with kappa values ≥0.65 except for item 5, Dyskinetic pains (j = 0.44), and the intraclass correlation coefficient (ICC) for the KPPQ total score was 0.98.
Introduction
The prevalence of pain in Parkinson's disease (PD) has been estimated to be around 68% (range 40%-85%) [1] . However, pain in PD is still underdiagnosed and often undeclared [2] , and only about half (52.4%) of PD patients with pain use analgesics [1] .
Furthermore, PD patients with pain are more likely to suffer from anxiety, depression and worsened sleep quality [3] . Pain has also been shown to interfere with work and other activities of daily living to some extent in these PD patients [4, 5] . Because of the multidimensional effect of pain in PD, it is one of the most relevant determinant factors of health-related quality of life in general [6] and in PD [7, 8] .
Several types of pain may be present in PD (e.g. dystonic, musculoskeletal, central and radicular) [9] and accumulate in a single patient, complicating the management of this non-motor symptom [10] . Moreover, the pathophysiology of pain in PD is complex, with peripherally related origins (rigidity, dystonia), spinalcord-related origins (intermediolateral cell column) and brain-related origins (deficiency of monoamines in the brain stem) [11, 12] .
Because of their inherent difficulty for assessment, the rater-based King's Parkinson's Disease Pain Scale (KPPS) was developed to evaluate the multiple pain modalities present in PD patients [13] . However, the KPPS is administered by healthcare professionals; therefore, a need for a valid patient-completed questionnaire exists. For this reason, the King's College Parkinson's Disease Pain Questionnaire (KPPQ) was created with the support of CRISP (Community for Involvement and Support for People with Parkinson's), an expert patient group based at King's College Hospital, to ensure comprehensibility for laypersons by using appropriate wording and logically ordering the questions.
The KPPQ (Appendix S2), a time-efficient and easy-to-understand 14-item screening questionnaire, is composed solely of 'Yes' or 'No' questions that assess whether or not a specific type of pain is present, similarly to the widely used Non-Motor Symptoms Questionnaire (NMSQ) [14] . Since the patient-completed KPPQ is a derivative of the rater-completed KPPS, each question of the KPPQ corresponds to one of the items of the KPPS. Even though the KPPQ does not use domains to group these 14 items, both the KPPS and the KPPQ address the same specific types of pain.
The objective of this multicentre study was to determine the validity and reliability of the KPPQ using a sample of PD patients and healthy controls.
Methods

Design
This was an international, multicentre, observational, cross-sectional study.
Patients
Consecutive PD patients with a diagnosis of PD according to the UK PD Brain Bank criteria [15] who answered 'yes' to question 10 of the NMSQ, 'Unexplained pains (not due to known conditions)' [14] , were included in this study. Exclusion criteria were (i) patients with alternative or uncertain diagnosis of Parkinson's and drug-induced Parkinson's; (ii) inability to give consent; (iii) presence of dementia formally diagnosed following internationally accepted criteria; and (iv) diagnosis of identifiable conditions causing pain unrelated to PD (e.g. severe osteoarthritis, known malignancy, rheumatoid arthritis, polymyalgia rheumatica, fibromyalgia etc.).
For this study, a sample size of 300 patients was proposed considering both the potential variability and confounding effect of a patient-completed assessment and the number of participating sites.
Patients were recruited from August 2013 to February 2016 from movement disorder units of nine different centres across the UK as well as Romania. In the UK, the study was adopted in the National Institute of Health Research portfolio of studies (UKCRN No. 13344).
Controls
A sample of 150 controls (ratio of patients to controls 2:1) matched by age and sex was assessed by means of the KPPQ. Exclusion criteria overlapped exclusion criteria (ii)-(iv) for patients.
Assessments
For both patients and controls, information regarding socio-demographic and PD historical data were recorded.
In addition to the KPPQ, the following instruments for PD were applied (Appendix S1): KPPS [13] , Hoehn and Yahr classification (HY) [16] , Scales for Outcomes in Parkinson's Disease -Motor (SCOPAMotor) [17] , Non-Motor Symptoms Scale (NMSS) [18] , Clinical Impression of Severity Index for PD [19] , Visual Analogue Scale (VAS) for pain severity and frequency [20] , Hospital Anxiety and Depression Scale (HADS) [21] , EQ-5D [22] , PD Quality of Life Questionnaire (PDQ-8) [23] and Parkinson's Disease Sleep Scale -Version 2 (PDSS-2) [24] .
Levodopa equivalent dose was calculated according to Tomlinson et al. [25] .
In the control group, the following assessments were collected: KPPQ, HADS and EQ-5D.
Procedures
Patients were assessed in the optimally 'on' state. Test-retest reliability of the KPPQ was evaluated by means of a second application of the questionnaire in patients who remained stable with respect to pain as per the pain VAS.
Ethical issues
This study was approved by the hospital ethical committees/institutional review boards of the participating centres. All participants provided informed consent prior to joining the study.
Data analysis
For each participant, a KPPQ total score (KPPQ-TS) was calculated by summing the number of 'yes' responses. Also, to compare the performance of the KPPQ with the KPPS which was taken as the 'gold standard', the KPPQ items were grouped in domains according to those of the scale. For both the NMSQ and NMSS, the prevalence of the diverse types of pain was determined by the proportion of individuals responding positively to each item (score ≥1), considering a score of 0 as the absence of the symptom.
Distribution of data was not normal (Shapiro-Francia test); therefore, non-parametric statistics were used. The differences between patients and controls were analysed using the chi-squared, Mann-Whitney U and McNemar chi-squared tests. The association between measures was determined by the Spearman rank correlation coefficient. A high correlation (r S > 0.70) of the KPPQ-TS with KPPS total score was hypothesized, whereas moderate or weak correlations (r S ≤ 0.70) [26] were expected with other variables.
For concordance between the prevalence detected by corresponding items of the KPPQ and KPPS, and for test-retest reliability, Cohen's kappa index for items and the intraclass correlation coefficient (ICC) for total scores were determined.
Finally, sensitivity, specificity, positive and negative predictive values, and accuracy of the KPPQ were calculated against the corresponding components of the KPPS.
For more details see Appendix S1.
Results
Data from 300 patients and 150 controls matched by age and gender are reported. There were no significant differences between patients and controls with reference to age (mean AE SD, 64.86 AE 10.54 vs.
64.86 AE 10.23; P = 0.90), sex (males, 59.7% vs. 60%; P = 0.95), ethnicity (P = 0.63) and education years (14.11 AE 3.99 vs. 14.39 AE 3.93; P = 0.33). The median (and interquartile range) HY of patients was 2 (2-3; limits 1-5).
The HADS and EQ-5D assessments showed significantly higher levels of depression (6.62 AE 4.39), anxiety (5.45 AE 3.82) and worse quality of life (0.57 AE 0.27) in PD patients compared to the levels of depression (5.09 AE 3.57), anxiety (3.90 AE 3.01) and overall quality of life (0.78 AE 0.22) in controls (P < 0.0001 to P = 0.0006). Significant differences were also found in the proportion of subjects with positive responses on the KPPQ for 50% of the items and three of the seven domains after Bonferroni correction (Table 1) . Comparing KPPQ-TS, patients declared more pain symptoms than controls (3.96 AE 2.56 vs. 2.17 AE 1.39; P < 0.0001).
In patients, the proportions of positive responses to the KPPQ were compared with those of the KPPS, and a significant difference was found in only one item (6. Painful cramps during 'off' periods) of the KPPQ and one domain (3. Fluctuation-related pain) ( Table 1) .
The agreement between KPPQ and KPPS prevalence showed kappa values from 0.56 (KPPQ items 6 and 7) to 0.86 (item 14), with 11 items (78.6%) reaching kappa values >0.60 (substantial agreement). Overall, the KPPQ-TS and KPPS 'total score of prevalence' displayed a high level of concordance (ICC = 0.88). Table 2 shows the correlations of the KPPQ-TS with other pain measures. Whilst a tight correlation with the KPPS total score (r S = 0.80) was found, coefficients were weak/moderate with the other pain measures (r S = 0.31-0.46). The KPPS total score, however, showed mildly higher correlation coefficient values with these pain assessments (r S = 0.47-0.50).
To test the reproducibility of the KPPQ, a second application was carried out in 52 patients at a mean interval of 11.8 AE 4.4 days (range 7-28). No significant differences between applications were found for the VAS total score (Wilcoxon signed-rank test; P = 0.52) and the KPPQ-TS (P = 0.76). Kappa values were ≥0.65 for all KPPQ items with the exception of one item (5. Dyskinetic pains; j = 0.44; Table 3 ). The ICC for the KPPQ-TS was 0.98.
The results of the KPPQ diagnostic parameters were satisfactory, with values running from 61.4% to 99.3% (Table 4 ). The global accuracy of the KPPQ components ranged from 78.3% to 98.3%.
Discussion
This is the first report of a validation of a patientcompleted pain questionnaire specifically developed for PD. This patient-completed screening tool was derived from the KPPS and allows for the direct declaration of the pain each patient experiences. Prevalent in the prodromal, early, advanced and palliative stages of PD, pain is one of its most important non-motor symptoms [27] [28] [29] and was described by James Parkinson himself in his case number 4 [30, 31] . Neuropathological correlates of pain in early and untreated PD have been described [32] , and pain is also featured as one of the most prevalent and troublesome symptoms in the late palliative stage of PD [28, 33] .
Despite the importance and high frequency of pain in PD [34] , studies suggest that pain is under-reported and often not considered in clinical consultations [2] . In part, this is related to the lack of a validated selfdeclared tool specifically developed considering the diversity of pain in PD. The KPPQ was developed considering this conceptual framework and to empower patients to declare pain.
Our analysis showed that, when the KPPQ was applied in patients and matched controls, the prevalence of the different varieties of pain was significantly greater in PD patients in half of the pain modalities and in three out of the seven domains. These results are expected because pain is experienced by both the elderly and PD patients. However, when considering the differences between KPPQ-TS, patients declared significantly more symptoms than controls.
Consistent with previous findings, patients with pain displayed higher rates of depression and anxiety [3] . Some estimates show that chronic pain can increase the risk for depression, yet a link in the opposite direction is unclear [35] [36] [37] . It is hypothesized that the link between pain and depression could be due to neuroinflammation [36] . In PD, pain-related disability also correlates with depression and anxiety [38] .
Prior research has shown that pain is a determinant of quality of life in all populations [39] and that PD considerably degrades patients' health-related quality of life [40, 41] . The non-motor symptom burden of PD, which includes pain, can affect health-related quality of life with a greater impact than the motor symptoms [42] [43] [44] [45] .
The convergent validity of the KPPQ was assessed using other pain measures. Whilst weak and moderate correlations were found between these measures and the KPPQ, the KPPS showed higher levels of correlations with these scales. However, it is important to note that the KPPQ is only a screening tool, whereas the KPPS is a quantitative measure of pain severity and frequency in PD and is more closely related to the scales with which both were compared. Nevertheless, the KPPQ showed moderate correlations with PD-related variables (i.e. SCOPA -Motor, NMSS, Clinical Impression of Severity Index for PD, PDSS-2 and PDQ-8) as well as other measures (i.e. HADSAnxiety, HADS -Depression and EQ-5D). The weak correlation between the KPPQ and levodopa equivalent dose and between the KPPQ and HY staging suggests that there is no relation between PD progression and the number of pain symptoms experienced by the patient despite previous findings suggesting a relationship between pain and motor impairment severity [4] . Concerning the reproducibility of the KPPQ, there was significant agreement in each item between both applications of the KPPQ except for one (5. Dyskinetic pains) and for the KPPQ-TS. These findings lead to the conclusion that the KPPQ is an instrument with satisfactory reproducibility.
When comparing the KPPQ to the KPPS, there were significant differences in the proportion of positive responses for only one item and one domain. This can be explained by the differences in the wording of the corresponding item in the KPPQ (6. Painful cramps in a region during 'off' periods) and in the KPPS (5. Pain in a region during 'off' dystonia). Otherwise, there was significant agreement between KPPQ and KPPS prevalence for each item, suggesting that they are equivalent when the KPPS is used as a screening tool. There was also a high level of concordance and a strong correlation between the total scores for the two instruments.
Finally, the satisfactory capabilities of the KPPQ for screening are clear based on its high sensitivity, specificity and predictive values. Overall, the KPPQ was shown to detect with a high accuracy the presence of the diverse pain modalities in PD. Yet, a limitation of our study is the assumption that a variety of comorbidities may not cause significantly increased pain and may be evenly distributed amongst patients and controls. Therefore, comorbidities that may not necessarily cause pain, such as diabetes, were not controlled for.
However, from these results, it is inferred that the KPPQ is a useful, valid and reliable patient-completed instrument to assess pain in PD. It is proposed that KPPQ be provided to every patient who answers 'yes' to the relevant pain-related question in the NMSQ, which is now globally applied and regarded as a quality standard for the clinical assessment of PD. As both are patient-completed tools, they can be completed whilst waiting to be seen, optimizing consultation time. Utilization of this strategy in clinics would ensure that pain is not under-reported or under-recognized in clinical practice.
